
Data support pembrolizumab regimen as ‘new standard’ for advanced cervical cancer
Pembrolizumab plus chemoradiotherapy has shown to significantly improve overall survival for women with high-risk locally advanced cervical cancer. The FDA approved this regimen based on progression-free survival data from a phase 3 trial. Results presented at the ESMO Congress demonstrated a higher 36-month OS rate with pembrolizumab compared to a placebo. The regimen showed consistent…